1. Nature. 2016 Dec 1;540(7631):144-149. doi: 10.1038/nature20565. Epub 2016 Nov 
16.

In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted 
integration.

Suzuki K(1), Tsunekawa Y(2), Hernandez-Benitez R(1)(3), Wu J(1)(4), Zhu J(5)(6), 
Kim EJ(7), Hatanaka F(1), Yamamoto M(1), Araoka T(1)(4), Li Z(8), Kurita M(1), 
Hishida T(1), Li M(1), Aizawa E(1), Guo S(8), Chen S(8), Goebl A(1), Soligalla 
RD(1), Qu J(9)(10), Jiang T(6)(11), Fu X(5)(6), Jafari M(6), Esteban CR(1), 
Berggren WT(12), Lajara J(4), Nuñez-Delicado E(4), Guillen P(4)(13), Campistol 
JM(14), Matsuzaki F(2), Liu GH(10)(15)(16)(17), Magistretti P(3), Zhang K(8), 
Callaway EM(7), Zhang K(5)(6)(18)(19), Belmonte JC(1).

Author information:
(1)Gene Expression Laboratory, Salk Institute for Biological Studies, 10010 N. 
Torrey Pines Rd, La Jolla, California 92037, USA.
(2)Laboratory for Cell Asymmetry, RIKEN Center for Developmental Biology, 2-2-3 
Minatojima-Minamimachi, Chuo-ku, Kobe 650-0047, Japan.
(3)4700 King Abdullah University of Science and Technology (KAUST) Thuwal 
23955-6900, Saudi Arabia.
(4)Universidad Católica San Antonio de Murcia (UCAM) Campus de los Jerónimos, 
no. 135 Guadalupe 30107, Murcia, Spain.
(5)Guangzhou Women and Children's Medical Center, Guangzhou Medical University, 
Guangzhou 510623, China.
(6)Shiley Eye Institute, Institute for Genomic Medicine, Institute of 
Engineering in Medicine, University of California, San Diego, 9500 Gilman Drive 
#0946, La Jolla, California 92023, USA.
(7)Systems Neurobiology Laboratory, Salk Institute for Biological Studies, 10010 
N. Torrey Pines Rd., La Jolla, California 92037, USA.
(8)Bioengineering, University of California, San Diego, 9500 Gilman Drive, 
MC0412, La Jolla, California 92093-0412, USA.
(9)State Key Laboratory of Stem Cell and Reproductive Biology, Institute of 
Zoology, Chinese Academy of Sciences, Beijing 100101, China.
(10)University of Chinese Academy of Sciences, Beijing 100049, China.
(11)Guangzhou EliteHealth Biological Pharmaceutical Technology Company Ltd, 
Guangzhou 510005, China.
(12)Salk Institute for Biological Studies, 10010 N. Torrey Pines Rd, La Jolla, 
California 92037, USA.
(13)Fundación Dr. Pedro Guillen, Investigación Biomedica de Clinica CEMTRO, 
Avenida Ventisquero de la Condesa, 42, 28035 Madrid, Spain.
(14)Hospital Clinic, University of Barcelona, IDIBAPS, 08036 Barcelona, Spain.
(15)National Laboratory of Biomacromolecules, CAS Center for Excellence in 
Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 
100101, China.
(16)Key Laboratory of Regenerative Medicine of Ministry of Education, Institute 
of Aging and Regenerative Medicine, Jinan University, Guangzhou 510632, China.
(17)Beijing Institute for Brain Disorders, Beijing 100069, China.
(18)Molecular Medicine Research Center, West China Hospital, Sichuan University, 
Chengdu 610041, China.
(19)Veterans Administration Healthcare System, San Diego, California 92093, USA.

Comment in
    Nat Rev Genet. 2017 Jan;18(1):1. doi: 10.1038/nrg.2016.158.

Targeted genome editing via engineered nucleases is an exciting area of 
biomedical research and holds potential for clinical applications. Despite rapid 
advances in the field, in vivo targeted transgene integration is still 
infeasible because current tools are inefficient, especially for non-dividing 
cells, which compose most adult tissues. This poses a barrier for uncovering 
fundamental biological principles and developing treatments for a broad range of 
genetic disorders. Based on clustered regularly interspaced short palindromic 
repeat/Cas9 (CRISPR/Cas9) technology, here we devise a homology-independent 
targeted integration (HITI) strategy, which allows for robust DNA knock-in in 
both dividing and non-dividing cells in vitro and, more importantly, in vivo 
(for example, in neurons of postnatal mammals). As a proof of concept of its 
therapeutic potential, we demonstrate the efficacy of HITI in improving visual 
function using a rat model of the retinal degeneration condition retinitis 
pigmentosa. The HITI method presented here establishes new avenues for basic 
research and targeted gene therapies.

DOI: 10.1038/nature20565
PMCID: PMC5331785
PMID: 27851729 [Indexed for MEDLINE]

Conflict of interest statement: The authors declare no competing financial 
interests. Readers are welcome to comment on the online version of the paper.